Evidence map›Paper›PMID 28614627›Full record

Trial reportJournal of cachexia, sarcopenia and muscle2017

A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer.

Tora S Solheim, Barry J A Laird, Trude Rakel Balstad, Guro B Stene, Asta Bye, Neil Johns, Caroline H Pettersen, Marie Fallon, Peter Fayers, Kenneth Fearon and 1 more

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of cachexia, sarcopenia and muscle, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01419145 (A Feasibility Study of Multimodal Exercise/Nutrition/Anti-inflammatory Treatment for Cachexia - the Pre-MENAC Study), which is not on this map. Cited by 177 papers, 23 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
177citing papers in PubMed, 23 pooled it
16.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01419145 nacompletednot on this map

A Feasibility Study of Multimodal Exercise/Nutrition/Anti-inflammatory Treatment for Cachexia - the Pre-MENAC Study

TypeinterventionalSponsorNorwegian University of Science and TechnologyRan2011 to 2014Enrolled46ConditionsCancer, CachexiaArmsMultimodal intervention, Standard care
3 · Its place in the literature

Who cites it

177 citing papers in PubMed, 23 syntheses or guidelines pooled it, 304 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Comparison of EPA and DHA&EPA on body weight, BMI, and lean body mass in cancer patients: a network meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Multimodal interventions for cachexia management.The Cochrane database of systematic reviews · 2025
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Guideline
  15. Exercise for cancer cachexia in adults.The Cochrane database of systematic reviews · 2021
    Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. A systematic review examining nutrition support interventions in patients with incurable cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020
    Pooled it
  20. Combined exercise and nutritional rehabilitation in outpatients with incurable cancer: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019
    Pooled it

117 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

Tora S SolheimEuropean Palliative Care Research Centre (PRC), Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Barry J A LairdEuropean Palliative Care Research Centre (PRC), Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Trude Rakel BalstadEuropean Palliative Care Research Centre (PRC), Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Guro B SteneCancer Clinic, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
Asta ByeRegional Advisory Unit for Palliative Care, Department of Oncology, Oslo University Hospital, Oslo, Norway.
Neil JohnsDepartment of Surgery, School of Clinical Sciences, University of Edinburgh, Little France Crescent, Edinburgh, UK.
Caroline H PettersenEuropean Palliative Care Research Centre (PRC), Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Marie FallonEdinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK.
Peter FayersEuropean Palliative Care Research Centre (PRC), Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Kenneth FearonDepartment of Surgery, School of Clinical Sciences, University of Edinburgh, Little France Crescent, Edinburgh, UK.
Stein KaasaEuropean Palliative Care Research Centre (PRC), Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Norwegian University of Science and Technology · NOSt Olav's University Hospital · NOUniversity of Edinburgh · GBEdinburgh Cancer Research · GBKITH (Norway) · NOOslo University Hospital · NO

Funding

Marie Curie MCCC-RP-16-A20997
6 · The paper itself

Abstract

backgroundCancer cachexia is a syndrome of weight loss (including muscle and fat), anorexia, and decreased physical function. It has been suggested that the optimal treatment for cachexia should be a multimodal intervention. The primary aim of this study was to examine the feasibility and safety of a multimodal intervention (n-3 polyunsaturated fatty acid nutritional supplements, exercise, and anti-inflammatory medication: celecoxib) for cancer cachexia in patients with incurable lung or pancreatic cancer, undergoing chemotherapy.

methodsPatients receiving two cycles of standard chemotherapy were randomized to either the multimodal cachexia intervention or standard care. Primary outcome measures were feasibility assessed by recruitment, attrition, and compliance with intervention (>50% of components in >50% of patients). Key secondary outcomes were change in weight, muscle mass, physical activity, safety, and survival.

resultsThree hundred and ninety-nine were screened resulting in 46 patients recruited (11.5%). Twenty five patients were randomized to the treatment and 21 as controls. Forty-one completed the study (attrition rate 11%). Compliance to the individual components of the intervention was 76% for celecoxib, 60% for exercise, and 48% for nutritional supplements. As expected from the sample size, there was no statistically significant effect on physical activity or muscle mass. There were no intervention-related Serious Adverse Events and survival was similar between the groups.

conclusionsA multimodal cachexia intervention is feasible and safe in patients with incurable lung or pancreatic cancer; however, compliance to nutritional supplements was suboptimal. A phase III study is now underway to assess fully the effect of the intervention.

Indexed as

AgedCachexiaCelecoxibCombined Modality TherapyDietary SupplementsDisease ManagementExerciseFemaleHumansLung NeoplasmsMaleMiddle AgedMultimodal ImagingNeoplasm StagingPancreatic NeoplasmsTreatment OutcomeCelecoxibAnti-inflammatoryCachexiaCancerMulti-modalRandomisedTrial

Identifiers

PMID28614627
PMCPMC5659068
OpenAlexW2626721982

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.